Rifat OZMEN, Necla DEĞER, Derya KARABULUT

Timokinonun izoproterenol ile indüklenen sıçan aortu üzerindeki sitoprotektif etkilerinin değerlendirilmesi

Amaç: Çalışmada isoproterenol (ISO) kaynaklı aort doku hasarına karşı timokinonun (THQ) sitoprotektif etkilerinin histolojik ve immunohistokimyasal olarak değerlendirilmesi amaçlanmıştır Gereç ve Yöntem: Sıçanlar dört gruba ayrıldı. (n=8). Kontrol grubu (Kontrol); tedavi uygulanmadı, Timokinon grubu (THQ); 20 mg / kg intragastrik (ig) 8 gün boyunca 24 saat aralıklarla THQ, Isoproterenol grubu (ISO); deneyin 7. ve 8. gününde 100 mg / kg subkutan (sc) ISO (1 ml steril distile suda çözüldü) 24 saat aralıklarla uygulandı. Timokinon+Isoproterenol grubu (THQ+ISO); THQ ig 20 mg/kg 8 gün boyunca ve 100 mg/kg ISO deneyin 7. ve 8. gününde uygulandı. Sıçanların aort dokuları ve kanları alındı. Dokular hematoksilen eozin ve immunohistokimayasal olarak interlökin-6 (IL-6) ve interlökin-17 (IL-17) boyandı. TNF-α, kan serumlarında ELISA ile incelendi. Bulgular: ISO grubunda aort duvar kalınlığı kontrol ve THQ grubuna kıyasla arttı. Ayrıca bu grupta IL-6 ve IL-17 immunoreaktivitesi de artış gösterdi. IL-17 istatistiksel olarak anlamlıydı. THQ hem duvar kalınlığını hem de IL-6 ve IL-17 ekspresyon seviyelerini düzeltti. TNF-α, ISO grubunda azaldı, fakat gruplar arasında istatistiksel bir farklılık gözlenmedi. Sonuç: ISO kaynaklı aort doku hasarına karşı THQ sitoprotektif bir ajan olarak hizmet eder.

Anahtar Kelimeler:

Isoproterenol, timokinon, aort.

Evaluation of the cytoprotective effects of thymoquinone on isoproterenol-induced rat aorta

Purpose: The aim of this study was to evaluate histologically and immunohistochemically the cytoprotective effects of thymoquinone (THQ) against isoproterenol (ISO)-induced aortic tissue damage. Materials and Methods: Rats were divided into four groups (n=8). Control group (Control); were untreated rats, Thymoquinone group (THQ); 20 mg / kg intragastrically (ig) THQ at 24 hour intervals for 8 days, Isoproterenol group (ISO); on the 7th and 8th day of the experiment, 100 mg/kg subcutaneous (sc) ISO (dissolved in 1 ml sterile distilled water) was given at 24 hour intervals. Thymoquinone + Isoproterenol group (THQ+ISO); THQ was administered ig at 20 mg/kg for 8 days, and 100 mg/kg ISO was administered on day 7 and day 8 of the experiment. Aortic tissues and blood were collected from rats. Tissues were stained by hematoxylin-eosin and immunohistochemically by interleukin-6 (IL-6) and interleukin-17 (IL-17). TNF-α, ELISA was examined in blood sera. Results: Aortic wall thickness was found to be increased in the ISO group compared to the control and THQ groups. In addition, IL-6 and IL-17 immunoreactivity increased in this group. IL-17 height was statistically significant. THQ corrected both the increase in wall thickness and the expression levels of IL-6 and IL-17. TNF-α was found to be decreased in the ISO group, but no statistically significant difference was observed between the groups. Conclusion: THQ serves as a cytoprotective agent

Keywords:

Isoproterenol, thymoquinone, aorta.,

PDF

___

1. Sözen MA. Obezite ve obezitenin genetiği. Kocatepe Med J. 2006;7:1-11.
2. Tedik SE. Fazla kilo/obezitenin önlenmesinde ve sağlıklı yaşamın desteklenmesinde hemşirenin rolü. Turk J Diab Obes. 2017;2:54-62.
3. Altunkaynak BZ, Özbek E. Obezite: nedenleri ve tedavi seçenekleri. Van Med J. 2006;13:138-142.
4. Yanovski JA. Pediatric obesity. an introduction. Appetite. 2015;93:3-12.
5. Chesi A, Grant SFA. The genetics of pediatric obesity. Trends Endocrinol Metab. 2015;26:711-721.
6. Erkol A, Khorshid L. Obezite; predispozan faktörler ve sosyal boyutun değerlendirilmesi. SSK Tepecik Hast Derg. 2004;14:101-107.
7. Brown CL, Halvorson EE, Cohen GM, Lazorick S, Skelton JA. Addressing childhood obesity: opportunities for prevention. Pediatr Clin. 2015;62:1241–1261.
8. Stanik J, Kratzsch J, Landgraf K, Scheuermann K, Spielau U, Gausche R et al. Concordance of bioactive vs. total immunoreactive serum leptin levels in children with severe early onset obesity. PLoS One. 2017;12:e0178107.
9. Hyeong-Kyu P, Rexford SA. Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism. 2015;64:24-34.
10. Münzberg H, Morrison CD. Structure, production and signaling of leptin. Metabolism. 2015;64:13–23.
11. Alamri NS, Hussain A, Alzein EH, Al Jareedan TW, Al Dawood M, & Hamad MA et al. Leptin as a potential biomarker for childhood obesity? EC Paediatrics. 2017;3:435-446.
12. Aslan K, Serdar Z, Tokullugil HA. Multifonksiyonel hormon: leptin. Uludağ Üniversitesi Tıp Dergisi. 2004;30:113-118.
13. Farr OM, Gavrieli A, Mantzoros CS. Leptin applications in 2015: What have we learned aboutleptin and obesity? Curr Opin Endocrinol Diabetes Obes. 2015;22:353–359.
14. Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ et al. Leptin and obesity: role and clinical implication. Front Endocrinol. 2021;12:585887.
15. Comba A, Mert H, Comba B. Leptin ve metabolik etkileri. YYU Veteriner Fakültesi Derg. 2014;25:87- 91.
16. Marcella A, Adriana Di Trana, Bernardo V, Andrea C,Salvatore B, Anna De A et al. Leptin gene polymorphism in goats fed with diet at different energy level: effects on feed intake, milk traits, milk fatty acids composition, and metabolic state. Animals (Basel). 2019;9:424.
17. Seth SM, Atif Q, Muredach PR. Leptin resistance a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008;52:1201-10.
18. Elias CF, Purohit D. Leptin signaling and circuits in puberty and fertility. Cell Mol Life Sci. 2013;70:841– 862.
19. Dias NF, Fernandes AE, de Melo ME, & Reinhardt HL, Cercato C, Villares SMF et al. Lack of mutations in the leptin receptor gene in severely obese children. Arq Bras Endocrinol Metabol. 2012;56:178-83.
20. Facey A, Dilworth L, Irving R. A Review of the leptin hormone and the association with obesity and diabetes mellitus. J Diabetes Metab. 2017,8:3.
21. Tam CS, Lecoultre V, Ravussin E. Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther. 2011;11:1677–1685.
22. Khosropour S, Shojaee M, Lotfi P. Obesity, leptin and leptin receptors. Gene Cell Tissue. 2016;3:e39980.
23. Catli G, Anik A, Tuhan HU, Kume T, Bober E, Abaci A. The relation of leptin and soluble leptin receptor levels with metabolic and clinical parameters in obese and healthy children. Peptides. 2014;56:72-76.
24. Huvenne H, Le Beyec J, Pépin D, Alili R, Kherchiche PP, Jeannic E et al. Seven novel deleterious LEPR mutations found in aarly-onset obesity: an exon6–8 shared by subjects from reunion island, France, suggests a founder effect. J Clin Endocrinol Metab. 2015;100: E757–E766.
25. Şahin S, Rüstemoğlu A, Tekcan A, Taşlıyurt T, Güven H, Yığıt S. Investigation of associations between obesity and LEP G2548A and LEPR 668A/G polymorphisms in a Turkish population. Dis Markers. 2013;35: 673–677.
26. Roszkowska-Gancarz M, Kurylowicz A, Polosak J, Mossakowska M, Franek E, Puzianowska-Kuźnicka M. Functional polymorphisms of the leptin and leptin receptor genes are associated with longevity and with the risk of myocardial infarction and of type 2 diabetes mellitus. Endokrynol Pol. 2014;65:11-6.
27. Angel-Chavez LI, Tene-Perez CE, & Castro E. Leptin receptor gene K656N polymorphism is associated with low body fat levels and elevated high-density cholesterol levels in Mexican children and adolescents. Endocr Res. 2012;124-34.
28. Mizuta E, Kokubo Y, Yamanaka I, Miyamoto Y, Okayama A, Yoshimasa Y et al. Leptin gene and leptin receptor gene polymorphisms are associated with sweet preference and obesity. Hypertens Res. 2008;31:1069–1077.
29. Oliveira R, Cerda A, Genvigir FDV, Sampaio MF, Armaganijan D, Bernik MMS et al. Leptin receptor gene polymorphisms are associated with adiposity and metabolic alterations in Brazilian individuals. Arq Bras Endocrinol Metabol. 2013;57:677-684.
30. Ma˘rginean CO, Ma˘rginean C, Voida˘zan S, Melit L, Crauciuc A, Duicu C et al. Correlations between leptin gene polymorphisms 223 A/G, 1019 G/A, 492 G/C, 976 C/A, and anthropometrical and biochemical parameters in children with obesity. Medicine (Baltimore). 2016;95:e3115.